WB
LXRX icon

WesBanco Bank’s Lexicon Pharmaceuticals LXRX Stock Holding History

WesBanco Bank’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,929
Closed -$67K – 546
2014
Q2 		$67K Hold
5,929
– – ﹤0.01% 520
2014
Q1 		$72K Buy
+5,929
New +$75.8K ﹤0.01% 517

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WesBanco Bank's LXRX Position: Q3 2014 in Review

WesBanco Bank sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2014, closing a stake of 5,929 shares — an estimated $67K sold.

WesBanco Bank first reported a position in LXRX in Q1 2014 and held it in 2 quarters. The position peaked at $72K in Q1 2014. 104 funds tracked by Wall St. Rank hold LXRX as of Q3 2014.

  • WesBanco Bank reported no remaining Lexicon Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • WesBanco Bank sold 5,929 Lexicon Pharmaceuticals shares in Q3 2014, an estimated $67K.
  • WesBanco Bank first reported a position in Lexicon Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • WesBanco Bank's Lexicon Pharmaceuticals position peaked at $72K in Q1 2014.
  • 104 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2014.

Based on WesBanco Bank's 13F filing for Q3 2014, filed 6 Nov 2014.